Conversely, both pharmacological and genetic inductions of GLT‐1 expression alleviate the pathological progression in mouse models of amyotrophic lateral sclerosis (Guo et al. 2003; Rothstein et al. 2005), Alzheimer's disease (Zumkehr et al. 2015; Hefendehl et al. 2016; Takahashi et al. 2015; Brymer et al. 2023) and Huntington's disease (Miller et al. 2008). Here, SLC1A2 is linked to early-onset autosomal dominant Alzheimer disease.